التفاصيل البيبلوغرافية
| العنوان: |
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. |
| المؤلفون: |
Richarz, Nina Anika, Puig, Luis, Pérez, Noelia, Cuadra-Urteaga, Jose, Elez, Elena, Fernández-Figueras, Maria Teresa |
| المصدر: |
Cancer Biology & Therapy; 2019, Vol. 20 Issue 3, p237-239, 3p |
| مستخلص: |
Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for treatment of metastatic melanoma in 2011, only two cases of neutrophilic panniculitis in malignancies other than melanoma have been published. Histiocytoid infiltrates of immature neutrophils resembling histiocytes or myelocytes have been reported in Sweet's syndrome and rarely in other neutrophilic dermatoses. We describe a novel variant of neutrophilic panniculitis with histiocytoid myeloid cells in an early lesion from a patient treated with vemurafenib in combination with an anti-EGFR (epidermal growth factor receptor) agent for metastatic colon carcinoma, three weeks after initiation of therapy. Recognizing this variant of panniculitis associated to BRAFi can avoid misinterpretation of the atypical subcutaneous infiltrate as myeloid leukaemia cutis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Biology & Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder